<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04497857</url>
  </required_header>
  <id_info>
    <org_study_id>epinet</org_study_id>
    <nct_id>NCT04497857</nct_id>
  </id_info>
  <brief_title>Academic-Community EPINET (AC-EPINET)</brief_title>
  <acronym>AC-EPINET</acronym>
  <official_title>Academic-Community EPINET (AC-EPINET): Mitigating Barriers to Care PILOT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tulane University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to examine the effects of CSC services delivered via TH (CSC-TH)&#xD;
      versus the standard clinic-based CSC model (CSC-SD) on engagement and outcomes in a 12-month,&#xD;
      randomized trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      180 subjects will be randomized into a 12 month study, to one of two treatment arms. The&#xD;
      investigators will assess four important elements of engagement to determine which are most&#xD;
      sensitive to TH treatment and mediates effects on hospitalization rates. The investigators&#xD;
      will assess acceptability and satisfaction of CSC-TH compared to CSC-SD, and deliver a&#xD;
      training manual for implementing TH in CSC clinics and for use in future research. Although&#xD;
      this study has exploratory aims consistent with pilot projects, The investigators have&#xD;
      incorporated methodological rigor where possible (randomization, powering for hospitalization&#xD;
      rate) in order to achieve the most robust data to assess the main study questions and inform&#xD;
      future trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized hospitalization rates</measure>
    <time_frame>12 months</time_frame>
    <description>To determine if CSC-TH, as compared to CSC-SD, is associated with superior clinical outcomes by counting the number of hospitalizations in a year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants hospitalized</measure>
    <time_frame>12 months</time_frame>
    <description>Count of the number of participants hospitalized (adjusted for time in treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time (days) to first hospitalization</measure>
    <time_frame>12 months</time_frame>
    <description>Count of the time in days to first hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom and functioning outcomes assessed by the MIRECC-GAF</measure>
    <time_frame>12 months</time_frame>
    <description>The MIRECC GAF is a three scale assessment of symptom severity, occupational/school functioning, and social functioning. It is scored from 0-100, with a lower score representing worse symptoms/functioning and higher scores representing better functioning. This assessment has been found to have high levels of reliability, concurrent, and predictive validity. It is completed by a trained rater and is expected to take 5 minutes to complete, as the information needed to score the participants will be gathered in various aspects of the assessment process.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <condition>Schizophreniform Disorders</condition>
  <condition>Major Depression With Psychotic Features</condition>
  <condition>Bipolar Disorder With Psychotic Features</condition>
  <arm_group>
    <arm_group_label>CSC-SD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard clinic-based CSC model treatment. Treatment will be delivered largely in clinic for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSC-TH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telehealth based CSC model treatment. Treatment will be delivered largely through telehealth for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Coordinated Specialty Care (CSC)</intervention_name>
    <description>CSC care is an evidenced-based, comprehensive specialty care programs for young people in the initial phases of psychotic disorders</description>
    <arm_group_label>CSC-SD</arm_group_label>
    <arm_group_label>CSC-TH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Between 16 and 35 years of age&#xD;
&#xD;
          2. Able to give informed consent&#xD;
&#xD;
          3. Willing and able to adhere to the study schedule&#xD;
&#xD;
          4. New intakes enrolled in one of the six clinical programs&#xD;
&#xD;
          5. Non-affective (schizophrenia, schizoaffective, schizophreniform) and affective (major&#xD;
             depression with psychotic features, bipolar disorder with psychotic features)&#xD;
             psychotic disorders with onsets within 5 years of enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Known IQ &lt; 70 based on participant report&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Breier</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana Univeristy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Megan Gaunnac</last_name>
    <phone>3178808435</phone>
    <email>mmdelane@iupui.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrew Visco</last_name>
    <phone>3178808438</phone>
    <email>avisco@iupui.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Recovery from Early Psychosis Program (REPP) - Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Morris Goldman</last_name>
      <phone>312-503-0866</phone>
      <email>mgoldman@nm.org</email>
    </contact>
    <investigator>
      <last_name>Morris Goldman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prevention and Recovery Center for Early Psychosis</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Megan Gaunnac, MBA</last_name>
      <phone>317-880-8495</phone>
      <email>iupdp@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Alan Breier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Early Psychosis Intervention Clinic-New Orleans (EPIC-NOLA) - Tulane University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70119</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ashley Weiss</last_name>
      <phone>504-236-5009</phone>
      <email>aweiss3@tulane.edu</email>
    </contact>
    <investigator>
      <last_name>Ashley Weiss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Program for Risk Evaluation and Prevention (PREP) - University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ivy Tso</last_name>
      <phone>734-232-0373</phone>
      <email>ivytso@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Ivy Tso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Strong Ties Young Adults Program- University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Steven Silverstein</last_name>
      <phone>585-275-6742</phone>
      <email>Steven_Silverstein@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Silverstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt's Early Psychosis Program - Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Taylor Gautier</last_name>
      <phone>615-875-1401</phone>
      <email>taylor.gautier@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Stephan Heckers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 31, 2020</study_first_submitted>
  <study_first_submitted_qc>July 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2020</study_first_posted>
  <last_update_submitted>February 27, 2021</last_update_submitted>
  <last_update_submitted_qc>February 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Alan Breier</investigator_full_name>
    <investigator_title>Senior Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>psychosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

